194 related articles for article (PubMed ID: 31812590)
1. MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy.
Hanania AN; Kudchadker RJ; Bruno TL; Tang C; Anscher MS; Frank SJ
Brachytherapy; 2020; 19(1):38-42. PubMed ID: 31812590
[TBL] [Abstract][Full Text] [Related]
2. Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy.
Boyce-Fappiano D; Bathala TK; Ye R; Pasalic D; Gjyshi O; Pezzi TA; Noticewala SS; McGinnis GJ; Maroongroge S; Kuban DA; Nguyen QN; McGuire SE; Hoffman KE; Choi S; Tang C; Kudchadker RJ; Frank SJ
Brachytherapy; 2020; 19(5):574-583. PubMed ID: 32682778
[TBL] [Abstract][Full Text] [Related]
3. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
4. Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning.
Yan C; Huq MS; Heron DE; Beriwal S; Wynn RB
Brachytherapy; 2019; 18(3):338-347. PubMed ID: 30655047
[TBL] [Abstract][Full Text] [Related]
5. Is intraoperative nomogram-based overplanning of prostate implants necessary?
D'Souza WD; Lee HK; Palmer MB; Smith LG; Pollack A
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):462-7. PubMed ID: 12738321
[TBL] [Abstract][Full Text] [Related]
6. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
7. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of intraoperative dosimetry for prostate brachytherapy using registered ultrasound and fluoroscopy.
Lee J; Hobbs RF; Zahurak M; Ng SK; Zhang Z; Burdette EC; DeWeese TL; Song DY
Brachytherapy; 2018; 17(6):858-865. PubMed ID: 30217432
[TBL] [Abstract][Full Text] [Related]
9. Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125.
Shirvani SM; Kudchadker RJ; Bruno TL; Likhacheva A; Swanson DA; Frank SJ
Brachytherapy; 2011; 10(4):269-74. PubMed ID: 21296031
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
Stone NN; Hong S; Lo YC; Howard V; Stock RG
Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of clinically relevant dosimetric parameters to contouring uncertainty in postimplant dosimetry of low-dose-rate prostate permanent seed brachytherapy.
Mashouf S; Safigholi H; Merino T; Soliman A; Ravi A; Morton G; Song WY
Brachytherapy; 2016; 15(6):774-779. PubMed ID: 27720310
[TBL] [Abstract][Full Text] [Related]
12. The Anderson nomograms for permanent interstitial prostate implants: a briefing for practitioners.
Cohen GN; Amols HI; Zelefsky MJ; Zaider M
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):504-11. PubMed ID: 12023156
[TBL] [Abstract][Full Text] [Related]
13. MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer.
Takiar V; Pugh TJ; Swanson D; Kudchadker RJ; Bruno TL; McAvoy S; Mahmood U; Frank SJ
Brachytherapy; 2014; 13(1):68-74. PubMed ID: 23669149
[TBL] [Abstract][Full Text] [Related]
14. Reducing seed waste and increasing value of dynamic intraoperative implantation of Pd-103 seeds in prostate brachytherapy.
Taylor PK; Riegel AC
J Appl Clin Med Phys; 2018 Sep; 19(5):383-388. PubMed ID: 30003681
[TBL] [Abstract][Full Text] [Related]
15. Brachytherapy in patients with small prostate glands.
Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy.
Crook J; Patil N; Ma C; McLean M; Borg J
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1079-84. PubMed ID: 19879700
[TBL] [Abstract][Full Text] [Related]
17. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract][Full Text] [Related]
18. MR and CT image fusion for postimplant analysis in permanent prostate seed implants.
Polo A; Cattani F; Vavassori A; Origgi D; Villa G; Marsiglia H; Bellomi M; Tosi G; De Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1572-9. PubMed ID: 15590189
[TBL] [Abstract][Full Text] [Related]
19. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes.
Kovtun KA; Wolfsberger L; Niedermayr T; Sugar EN; Graham PL; Murciano-Goroff Y; Beard C; D'Amico AV; Martin NE; Orio PF; Nguyen PL
Brachytherapy; 2014; 13(2):152-6. PubMed ID: 23911279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
